Emerging Company Profile: Austria’s OncoOne could have an anticancer biologic which targets oxidized macrophage migration inhibitor factor ready for the...
The Swiss company's asthma triplet is now approved in Europe and Japan but Enerzair is well behind GSK's rival LABA/LAMA/ICS...
Novavax has progressed into Phase I trials with relatively little funding, but backing from Operation Warp Speed makes it a...
Regeneron and NIAID kick off a Phase III prevention trial for antibody cocktail REGN-COV2.
USITC’s initial decision in the Medytox and Daewoong botulinum dispute is favorable to Medytox and poised to take a toll...
Gesynta’s SEK190m ($20m) private placement allows its lead asset to enter Phase IIa studies for treating chronic inflammatory conditions in...
From cell therapy to digital health, from fast follower to innovator, China continues to gain traction with global health companies...
US pharma giant joins Singapore alliance aiming to encourage regional startups and innovation, in multiple tech-related areas including digital health...
After accelerated approval in the US in April based on Phase II response rates, the company will seek full approval...
Positive data from a second Phase III trial will support regulatory filings for linzagolix in the US and Europe, but...